Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: Prognostic significance

Cancer

Volumn 97, Issue 6, 2003, Pages 1376-1386

  Michels, Jean Jacques Michels ^a   Duigou, Françoise ^a   Marnay, Jacques ^a   Henry Amar, Michel ^a   Delozier, Thierry ^a   Denoux, Yves ^a   Chasle, Jacques ^a  

^a CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Breast; Cyclin A; Flow cytometry; Invasive ductal carcinoma; Ki 67; p21waf1; p53; S phase fraction

Indexed keywords

CYCLIN A; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL FEATURE; DNA DETERMINATION; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL CYCLE; CELL DIVISION; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037443793     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11209     Document Type: Article

References (116)

1. Rosai J. Breast. In: Rosai J. Ackerman's surgical pathology. St Louis: Mosby, 1996:1565-1660.
2. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
3. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14:2843-2877.
4. American Society of Clinical Oncology. 1997 Update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1998; 16:793-795.
5. Duigou F, Herlin P, Marnay J, Michels JJ. Variation of flow cytometric DNA measurement in 1485 primary breast carcinomas according to guidelines for DNA histogram interpretation. Cytometry. 2000;42:35-42.
6. Michels JJ, Duigou F, Marnay J. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat. 2000;62:117-126.
7. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry. 1993;14:482 485.
8. Gao CY, Zelenka PS. Cyclins, cyclin-dependent kinases and differentiation. Bioessays. 1997;19:307-315.
9. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986;320:84-85.
10. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979;278:261-263.
11. Linzer DI, Levine AJ. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. CelL 1979;17:43-52.
12. Marx J. How p53 suppresses cell growth. Science. 1993;262:1644-1645.
13. Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjold B. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. The South-East Sweden Breast Cancer Group. Int J Cancer. 1992;51:28-33.
14. Lawry J, Rogers K, Duncan JL, Potter CW. The identification of informative parameters in the flow cytometric analysis of breast carcinoma. Eur J Cancer. 1993;29A:719-723.
15. Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat. 1993;28:9-20.
16. Stal O, Carstensen J, Hatschek T, Nordenskjold B. Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients. Br J Cancer. 1992;66:706-711.
17. Visscher DW, Zarbo RJ, Jacobsen G, et al. Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry. Clinicopathologic correlations. Lab Invest. 1990;62:370-378.
18. Baldetorp B, Ferno M, Fallenius A, et al. Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry. 1992;13:577-585.
19. Stal O, Wingren S, Carstensen J, et al. Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol. 1989;25:301-309.
20. Ferno M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D. Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol. 1992;31:157-165.
21. Ewers SB, Attewell R, Baldetorp B, Borg A, Langstrom E, Killander D. Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat. 1992;20:93-108.
22. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990; 322:1045-1053.
23. Silvestrini R, Daidone MG, Del Bino G, et al. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol. 1993;4:213-219.
24. Remvikos Y, Gerbault-Seureau M, Magdelenat H, Prieur M, Dutrillaux B. Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. Breast Cancer Res Treat. 1992;23:43-49.
25. Christov K, Milev A, Todorov V. DNA aneuploidy and cell proliferation in breast tumors. Cancer. 1989;64:673-679.
26. Muss HB, Kute TE, Case LD, et al. The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer. 1989;64:1894-1900.
27. Chassevent A, Geslin J, Bertrand G, et al. Place de l'analyse de DNA par cytométrie en flux dans l'évaluation du pronostic des cancers du sein. Bull Cancer. 1990;77(Suppl 1):149S-154S.
28. Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fossa SD, Tveit KM. Flow cytometric DNA analysis as prognostic factor in human breast carcinoma. Pathol Res Pract. 1993; 189:405-410.
29. McDivitt RW, Stone KR, Craig RB, Palmer JO, Meyer JS, Bauer WC. A proposed classification of breast cancer based on kinetic information: derived from a comparison of risk factors in 168 primary operable breast cancers. Cancer. 1986;57:269-276.
30. Bergers E, van Diest PJ, Baak JP. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical, and pathologic variables. MMMCP Collaborative Group. Multicenter Morphometric Mammary Carcinoma Project Collaborative Group. Cancer. 1996;77:2258-2266.
31. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer. 1988;61:420-427.
32. Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjold B. Interrelations between cellular DNA content, S-phase fraction, hormone receptor status and age in primary breast cancer. A series of 1342 consecutively detected tumors. South-East Sweden Breast Cancer Group. Acta Oncol. 1992;31:283-292.
33. Stal O, Dufmats M, Hatschek T, et al. S-phase fraction is a prognostic factor in Stage I breast carcinoma. J Clin Oncol. 1993;11:1717-1722.
34. Wingren S, Stal O, Sullivan S, Brisfors A, Nordenskjold B. S-phase fraction after gating on epithelial cells predicts recurrence in node-negative breast cancer. Int J Cancer. 1994; 59:7-10.
35. Chassevent A, Jourdan ML, Romain S, et al. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res. 2001;7:909-917.
36. Pinto AE, Andre S, Soares J. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol. 1999;52:604-611.
37. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. j Clin Pathol. 2001;54:543-549.
38. Klintenberg C, Stal O, Nordenskjold B, Wallgren A, Arvidsson S, Skoog L. Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat. 1986; 7(Suppl):S99-S106.
39. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989;320:627-633.
40. Clark GM, Wenger CR, Beardslee S, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer. 1993;71(Suppl):2157-2162.
41. Sigurdsson H, Baldetorp B, Borg A, et al. Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer. 1990;62:786-790.
42. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer. 2001;93:283-287.
43. Collecchi P, Santoni T, Gnesi E, et al. Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. Cytometry. 2000;42:254-260.
44. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996;69:247-253.
45. Bouzubar N, Walker KJ, Griffiths K, et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer. 1989;59:943-947.
46. Gasparini G, Dal Fior S, Pozza F, Bevilacqua P. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat. 1989;14:329-336.
47. Locker AP, Birrell K, Bell JA, et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol. 1992;18:224-229.
48. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 1993;53:4665-4669.
49. Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat. 1996;37:57-64.
50. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995;71:146-149.
51. Stumpp J, Dietl J, Simon W, Geppert M. Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables. Gynecol Obstet Invest. 1992;33:47-50.
52. Gottardi O, Tabiadon D, Scanzi F, et al. [Clinical and prognostic usefulness of Ki67 determination in breast carcinoma]. Pathologica. 1992;84:15-22.
53. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol. 1995;104:42-49.
54. Leonardi E, Girlando S, Serio G, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992;45:416-419.
55. Weikel W, Beck T, Mitze M, Knapstein PG. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat. 1991;18:149-154.
56. Wiesener B, Hauser-Kronberger CE, Zipperer E, Dietze O, Menzel C, Hacker GW. p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression. Histopathology. 1998;33:522-530.
57. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996;2:585-592.
58. Fresno M, Molina R, Perez del Rio MJ, et al. p53 expression is of independent predictive value in lymph node-negative breast carcinoma. Eur J Cancer. 1997;33:1268-1274.
59. Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 1995; 72:1259-1266.
60. Barbareschi M, Caffo O, Doglioni C, et al. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 1996;74:208-215.
61. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res. 1996;2:1591-1599.
62. Leong AC, Hanby AM, Potts HW, et al. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer. 2000;20;89:26-31.
63. Bilous AM, McKay M, Milliken J. A comparison between Ki-67 antibody reactivity and other pathological variables in breast carcinoma. Pathology. 1991;23:282-285.
64. Clahsen PC, van de Velde CJ, Duval C, et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol. 1999;25:356-363.
65. Gonzalez-Vela MC, Garijo MF, Fernandez F, Val-Bernal JF. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol. 2001;16:399-406.
66. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990;65:11801184.
67. Lee AK, Wiley B, Loda M, et al. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol. 1992;5:61-67.
68. Lehr HA, Hansen DA, Kussick S, et al. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol. 1999;30:1314-1320.
69. McGurrin JF, Doria MI Jr., Dawson PJ, Karrison T, Stein HO, Franklin WA. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987;59: 1744-1750.
70. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol. 1999;17:470-477.
71. Gasparini G, Pozza F, Meli S, Reitano M, Santini G, Bevilacqua P. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. AnticancerRes. 1991; 11:2015-2021.
72. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol. 1997;36:369-374.
73. Steck K, Hunt K, Tucker S, Singletary S, el Naggar AK. Flow cytometric analysis of Ki-67 in invasive ductal carcinoma of the breast: correlation with tumor and patient characteristics. Oncol Rep. 1999;6:835-838.
74. Charpin C, Andrac L, Vacheret H, et al. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988;48:4368-4374.
75. Ioakim-Liossi A, Safioleas M, Karakitsos P, et al. p53 protein expression and proliferative activity in ductal breast carcinomas. Cytopathology. 2000;11:255-261.
76. Jeziorski A, Blonski JZ, Niewiadomska H. The expression of products of oncogenes c-erbB2 and EGFR and proliferating antigens Ki67 and PCNA in primary invasive ductal cancer of female breast. J Exp Clin Cancer Res. 2000;19:61-67.
77. Rudolph P, Alm P, Olsson H, et al. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol. 2001;32:311-319.
78. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991;67:421-428.
79. Wong SC, Chan JK, Lee KC, Hsiao WL. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol. 2001;194:35-42.
80. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res. 1996;2:147-154.
81. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol. 1993;100:213-217.
82. Midulla C, De Iorio P, Nagar C, et al. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res. 1999;19:4033-4037.
83. Querzoli P, Albonico G, Ferretti S, et al. MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol. 1996;49:926-930.
84. Rudolph P, MacGrogan G, Bonichon F, et al. Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat. 1999;55:61-71.
85. Bonetti A, Zaninelli M, Rodella S, et al. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Treat. 1996;38: 289-297.
86. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Marrano D, Mancini AM. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour. Ann Oncol. 1995;6:275-282.
87. Jiang M, Shao ZM, Wu J, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer. 1997;74:529-534.
88. McClelland RA, Gee JM, O'Sullivan L, et al. p21(WAF1) expression and endocrine response in breast cancer. J Pathol. 1999;188:126-132.
89. Rey MJ, Fernandez PL, Jares P, et al. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol. 1998;184:265-271.
90. Arisio R, Sapino A, Cassoni P, et al. What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas? J Clin Pathol. 2000;53:846-850.
91. Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994;219:332-341.
92. Montero S, Guzman C, Vargas C, Ballestin C, Cortes-Funes H, Colomer R. Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol. 2001;22:337-344.
93. Pratap R, Shousha S. Breast carcinoma in women under the age of 50: relationship between p53 immunostaining, tumour grade, and axillary lymph node status. Breast Cancer Res Treat. 1998;49:35-39.
94. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995;13:821-830.
95. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992;84:1109-1114.
96. van Slooten HJ, van de Vijver MJ, Borresen AL, et al. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J Pathol. 1999;189: 504-513.
97. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res. 2000;6:3923-3931.
98. Bebenek M, Bar JK, Harlozinska A, Sedlaczek P. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Anticancer Res. 1998;18:619-623.
99. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol. 1996;179:31-38.
100. Bevilacqua P, Verderio P, Barbareschi M, et al. Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat. 1996;37:123-133.
101. Gaglia P, Bernardi A, Venesio T, et al. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer. 1993;29A:1509-1513.
102. Imamura H, Haga S, Shimizu T, Watanabe O, Kajiwara T, Aiba M. MIB1-determined proliferative activity in intraductal components and prognosis of invasive ductal breast carcinoma. Jpn J Cancer Res. 1997;88:1017-1023.
103. Lee AK, Loda M, Mackarem G, et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome. Cancer. 1997;79:761-771.
104. Mandard AM, Denoux Y, Herlin P, et al. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density. Cancer. 2000;89:1748-1757.
105. Mitze M, Weikel W, Brumm C, Lippold R, Knapstein PG. [Effect of the proliferation rate on the course of node negative breast carcinoma]. Geburtshilfe Frauenheilkd. 1995;55:299-305.
106. Querzoli P, Albonico G, Ferretti S, et al. Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. Cancer. 1998;83:89-97.
107. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, von Smitten K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer. 1993;68:579-583.
108. Richter IM, Opri F, Torsten U, Weitzel H. [137 local recurrences after breast carcinoma - a retrospective study]. Geburtshilfe Frauenheilkd. 1996;56:198-203.
109. Veronese SM, Maisano C, Scibilia J. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res. 1995;15:2717-2722.
110. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993;71:3926-3931.
111. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer. 1997; 74:433-437.
112. Gohring UJ, Schondorf T, Kiecker VR, Becker M, Kurbacher C, Scharl A. Immunohistochemical detection of H-ras protooncoprotein p21 indicates favorable prognosis in nodenegative breast cancer patients. Tumour Biol. 1999;20:173-183.
113. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer. 2000;20;89:51-62.
114. Bankfalvi A, Tory K, Kemper M, et al. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract. 2000;196:489-501.
115. Eissa S, Khalifa A, el Gharib A, Salah N, Mohamed MK. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res. 1997; 17:1417-1423.
116. Ceccarelli C, Santini D, Chieco P, et al. Quantitative p21(waf-1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. Int J Cancer. 2001;20;95:128-134.